Kiniksa Pharmaceuticals International (KNSA) return on equity (ROE)

Return on equity · fiscal 2025
10.4%

Kiniksa Pharmaceuticals International (KNSA) earned a return on equity of 10.4% in fiscal 2025 (the year ended December 31, 2025). That is 20.2 percentage points higher than the -9.9% of fiscal 2024. Figures as of 17 Nov 2026, 22:24 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
10.4%
Change on fiscal 2024
+20.2 pts
Highest on record
46.3%fiscal 2022
Lowest on record
-85.3%fiscal 2021
Fiscal years on record
82018–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Kiniksa Pharmaceuticals International return on equity (ROE), in more detail

Across the 8 fiscal years on record (2018–2025), the highest was 46.3% in fiscal 2022 and the lowest -85.3% in fiscal 2021. The fiscal 2025 figure is higher than in 86% of the 7 earlier fiscal years on record, whose median is -37.0%.

History · 8 fiscal years

Return on equity by fiscal year

Kiniksa Pharmaceuticals International return on equity (ROE), year by year

Kiniksa Pharmaceuticals International (KNSA) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202510.4% 20.2 pts up
2024-9.9% 13.1 pts down
20233.2% 43.1 pts down
202246.3% 131.6 pts up
2021-85.3% 33.6 pts down
2020-51.7% 20.1 pts up
2019-71.8% 34.8 pts down
2018-37.0%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Kiniksa Pharmaceuticals International and comparable companies
CompanyReturn on equityFiscal year
Alkermes ALKS13.3%2025
PACS Group PACS20.2%2025
Kiniksa Pharmaceuticals International KNSA10.4%2025
ImmunityBio IBRX-130.7%2019
Cytokinetics CYTK-88.3%2021
ABIVAX ABVX-73.8%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KNSA

Kiniksa Pharmaceuticals International, figure by figure

Kiniksa Pharmaceuticals International (KNSA) overview: price, valuation and scorecardAll health care companies by market value

Kiniksa Pharmaceuticals International return on equity (ROE): questions and answers

What is Kiniksa Pharmaceuticals International's return on equity?

Kiniksa Pharmaceuticals International (KNSA) earned a return on equity of 10.4% in fiscal 2025 (the year ended December 31, 2025). That is 20.2 percentage points higher than the -9.9% of fiscal 2024.

Is Kiniksa Pharmaceuticals International's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 86% of the 7 earlier fiscal years on record, whose median is -37.0%.

What are the highest and lowest return on equity figures on record for Kiniksa Pharmaceuticals International?

Across the 8 fiscal years on record (2018–2025), the highest was 46.3% in fiscal 2022 and the lowest -85.3% in fiscal 2021.

How is Kiniksa Pharmaceuticals International's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kiniksa Pharmaceuticals International (KNSA) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/KNSA/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.